Renaissance Capital
CAI icon

Renaissance Capital’s Caris Life Sciences CAI Stock Holding History

Renaissance Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.43M Sell
46,542
-16,345
-26% -$367K 0.99% 26
2026
Q2 		$1.12M Buy
62,887
+19,403
+45% +$347K 0.62% 33
2026
Q1 		$826K Buy
43,484
+29,055
+201% +$635K 0.6% 30
2025
Q4 		$389K Sell
14,429
-14,031
-49% -$395K 0.28% 36
2025
Q3 		$861K Buy
+28,460
New +$908K 0.48% 29

Other funds holding CAI

Zevenbergen Capital Investments
Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Themes Management Co
Themes Management Co Greenwich, Connecticut $152M AUM 42.75% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Security National Bank
Security National Bank Omaha, Nebraska $865M AUM 30.55% 1-Year Est. Return

Renaissance Capital's CAI Position: Q3 2026 in Review

Renaissance Capital reduced its Caris Life Sciences (CAI) stake by 26% in Q3 2026, selling an estimated $367K and leaving 46,542 shares worth $1.43M. The position accounts for 0.99% of the portfolio, ranked #26.

Renaissance Capital first reported a position in CAI in Q3 2025 and has held it in 5 quarters since. 75 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Renaissance Capital held 46,542 shares of Caris Life Sciences worth $1.43M as of Q3 2026.
  • Renaissance Capital sold 16,345 Caris Life Sciences shares in Q3 2026, an estimated $367K.
  • Caris Life Sciences made up 0.99% of Renaissance Capital's portfolio in Q3 2026, its #26 holding.
  • Renaissance Capital first reported a position in Caris Life Sciences in Q3 2025 and has held it in 5 quarters since.
  • 75 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Renaissance Capital's 13F filing for Q3 2026, filed 23 Oct 2026.